APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

NCT03502330 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Advanced Melanoma
Non-small Cell Lung Cancer
Renal Cell Carcinoma

Interventions

DRUG: APX005M
DRUG: Cabiralizumab
DRUG: Nivolumab

Sponsor

Yale University

Collaborators

[object Object]
[object Object]
[object Object]